NCT05766371View on ClinicalTrials.gov

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2031

Conditions
Castrate Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerProstate CancerProstate Carcinoma
Interventions
DRUG

Pembrolizumab

Given IV

DRUG

177Lu-PSMA-617

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Prostate Cancer Foundation

OTHER

lead

University of California, San Francisco

OTHER